{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:43:25Z","timestamp":1778895805291,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/igc.0000000000000085","type":"journal-article","created":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T07:34:24Z","timestamp":1392881664000},"page":"528-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"Carlos","family":"Acevedo-Gadea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan A.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Urva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan-Arin","family":"Silasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maysa M.","family":"Abu-Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0000000000000085_bb0005","doi-asserted-by":"crossref","unstructured":"Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95:S105\u2013S143.","DOI":"10.1016\/S0020-7292(06)60031-3"},{"key":"10.1097\/IGC.0000000000000085_bb0010","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","article-title":"Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"22","author":"Fleming","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0000000000000085_bb0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/gyno.1996.0227","article-title":"A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study","volume":"62","author":"Ball","year":"1996","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0000000000000085_bb0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0090-8258(89)90605-7","article-title":"Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"33","author":"Thigpen","year":"1989","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0000000000000085_bb0025","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1200\/JCO.2004.02.088","article-title":"Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"22","author":"Thigpen","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0000000000000085_bb0030","first-page":"409a","article-title":"Phase II study of topotecan and cisplatinum for stages III and IV or for recurrent endometrial cancer","volume":"19","author":"Finkler","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"10.1097\/IGC.0000000000000085_bb0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/gyno.2002.6804","article-title":"A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study","volume":"87","author":"Miller","year":"2002","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0000000000000085_bb0040","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nature reviews. Nat Rev Drug Discov."},{"key":"10.1097\/IGC.0000000000000085_bb0045","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-11-0273","article-title":"Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models","volume":"10","author":"Squillace","year":"2011","journal-title":"Mol Cancer Ther."},{"key":"10.1097\/IGC.0000000000000085_bb0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1525-1438.2005.abst_21.x","article-title":"Novel biologic therapies for the treatment of endometrial cancer","volume":"15","author":"Wolf","year":"2005","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0000000000000085_bb0055","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer."},{"key":"10.1097\/IGC.0000000000000085_bb0060","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0000000000000085_bb0065","first-page":"5303","article-title":"Prevention of phosphatidylinositol 3\u2019-kinase-Akt survival signaling pathway during topotecan-induced apoptosis","volume":"60","author":"Nakashio","year":"2000","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0000000000000085_bb0070","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0000000000000085_bb0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0959-8049(01)00188-5","article-title":"A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer","volume":"38","author":"Gore","year":"2002","journal-title":"Eur J Cancer."},{"key":"10.1097\/IGC.0000000000000085_bb0080","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2001.19.19.3967","article-title":"Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer","volume":"19","author":"Clarke-Pearson","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0000000000000085_bb0085","first-page":"19","article-title":"Endometrial cancer: molecular and therapeutic aspects","volume":"169","author":"Tsikouras","year":"2013","journal-title":"EurJ Obstet Gynecol Reprod Biol."},{"key":"10.1097\/IGC.0000000000000085_bb0090","doi-asserted-by":"crossref","unstructured":"MS Colombo N, Schwartz P ,Kostka J, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. 2007;25:5516.","DOI":"10.1200\/jco.2007.25.18_suppl.5516"},{"key":"10.1097\/IGC.0000000000000085_bb0095","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin Cancer Res."},{"key":"10.1097\/IGC.0000000000000085_bb0100","first-page":"3373","article-title":"p53\/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin","volume":"61","author":"Huang","year":"2001","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0000000000000085_bb0105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation","volume":"120","author":"Beuvink","year":"2005","journal-title":"Cell."},{"key":"10.1097\/IGC.0000000000000085_bb0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2010.02.022","article-title":"A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and\/or recurrent gynecologic malignancies","volume":"117","author":"Temkin","year":"2010","journal-title":"Gynecol Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24057815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24057815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0000000000000085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:14:07Z","timestamp":1753233247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24057815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1048891X24057815"],"URL":"https:\/\/doi.org\/10.1097\/igc.0000000000000085","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0000000000000085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}